Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Agentase is a biotechnology company specializing in the development of enzyme-based sensors and decontamination products for chemical and biological defense. Founded as a spin-out from the University of Pittsburgh, the company leverages biocatalysis to create highly sensitive detection kits for nerve agents, organophosphates, and other toxic chemicals. Its flagship products, such as the Agentase Chemical Agent Disclosure (CAD) kits, provide rapid, colorimetric results for first responders and military personnel. The company's technology is also applicable to environmental monitoring and food safety. Agentase was acquired by FLIR Systems in 2010 to enhance their CBRNE (Chemical, Biological, Radiological, Nuclear, and Explosive) detection portfolio. Following the acquisition of FLIR by Teledyne Technologies in 2021, the technology is now part of the Teledyne FLIR division.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Agentase.